medi4893
mAbexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jan 1, 2013 (NCT01769417)
Timeline
Indications
Mechanism of action
- Alpha-hemolysinINHIBITOR
Alpha-hemolysin inhibitor
- Staphylococcus aureusImmunity, passive
Staphylococcus aureus immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3989997 ↗
Also known as
- medi4893
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05331885 | Phase 3 | Aug 31, 2022 | Aridis Pharmaceuticals, Inc., University of Lausanne |
| NCT02296320 | Phase 2 | Oct 10, 2014 | MedImmune |
| NCT01769417 | Phase 1 | Jan 1, 2013 | MedImmune |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MedImmune | For profit | 2 | 2 | 2 | 2013 |
| Aridis Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2022 |
| University of Lausanne | Academic/Hospital | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1